loader image

Pα+ Psychedelic Patent Analysis: March 2024

Reading Time: < 1 minute


General Overview
First Look at Nolan Williams et al.’s Ibogaine IP: Is Co-Administration of Magnesium and Ibogaine Common Practice?
Clexio Biosciences Protects CLE-100 Development Programs
Broad Strokes Attempt from Axsome Fails to Overcome Prior Art
NYU Abandons “Hot Psilocybin Patent Garbage”

***

Each month, we provide an interactive database of psychedelic patents that were granted, allowed, abandoned, rejected or that had responses filed.

We then provide detail and analysis on a handful of specific cases, or one deep dive.
Our monthly Psychedelic Patent Analysis is exclusively for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account.

Companies, organisations and candidates mentioned in this analysis: DemeRx, Axsome Therapeutics, Empyrean Neuroscience, Tactogen, Clexio Biosciences, CLE-100, Gilgamesh Pharmaceuticals, MindMed, Awakn Life Sciences, and others.



Source link

share this article
  • This field is for validation purposes and should be left unchanged.

Subscribe to receive the latest business and industry news in your inbox.

  • This field is for validation purposes and should be left unchanged.

latest from the industry
PSYCHEDELICS news

Whitepaper

  • This field is for validation purposes and should be left unchanged.

  • This field is for validation purposes and should be left unchanged.

Use